B. Riley Securities Begins Coverage of Kindly MD (NAKA) with a Buy Rating
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 17 2025
0mins
Should l Buy NAKA?
Source: NASDAQ.COM
B. Riley Securities Coverage: On October 16, 2025, B. Riley Securities initiated coverage of Kindly MD (NasdaqGM: NAKA) with a "Buy" recommendation, projecting a 977.51% upside based on an average one-year price target of $8.16/share.
Fund Sentiment and Ownership: There has been a 42.86% increase in the number of funds reporting positions in Kindly MD, although total shares owned by institutions decreased by 80.72% to 198K shares, with a bullish put/call ratio of 0.18 indicating positive market sentiment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NAKA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NAKA
Wall Street analysts forecast NAKA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.277
Low
1.00
Averages
1.25
High
1.50
Current: 0.277
Low
1.00
Averages
1.25
High
1.50
About NAKA
Kindly MD, Inc. is a Bitcoin-native holding company. The Company focuses on both healthcare and Bitcoin treasury management. It is focused on holistic pain management and reducing the impact of the opioid epidemic. Its specialty outpatient clinical services are reimbursed by Medicare, Medicaid, and commercial insurance contracts, as well as offered on a fee-for-service basis. The Company offers both in-person and telemedicine options for patients. It provides management of pain, functional medicine, cognitive behavioral therapy, addiction, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, medically managed weight loss, and hormone therapy. Its services include mental health, medical cards, medication management, sleep support, pain treatment, and weight loss. It operates the Bitcoin financial services line of business under the Nakamoto brand. Its wholly owned subsidiary is Nakamoto Holdings Inc.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
KindlyMD Rebrands to Nakamoto, Aligns with Bitcoin Strategy
- Corporate Rebranding: KindlyMD has rebranded to Nakamoto to align its corporate identity with its long-term strategy in the Bitcoin ecosystem, continuing healthcare operations through wholly-owned subsidiary Kindly LLC to ensure business continuity.
- Bitcoin Treasury Accumulation: The company has established a Bitcoin treasury worth over $500 million, enhancing its scalable operating and treasury platform through strategic investments and treasury asset allocations across multiple international markets.
- Share Repurchase Program: KindlyMD has authorized a share repurchase program, indicating confidence in its intrinsic value and potentially enhancing earnings per share by reducing the number of shares outstanding.
- Financial Performance: KindlyMD reported a GAAP EPS of -$0.42, missing expectations by $0.41, with revenue of $0.39 million slightly below projections, reflecting challenges during its transformation process.
See More
Nakamoto Inc. Rebrands to Align with Bitcoin Strategy, Holds Over $500 Million in Bitcoin Treasury
- Corporate Rebranding: Nakamoto Inc. has changed its name from KindlyMD, Inc. to Nakamoto Inc. to better align with its long-term strategy in the Bitcoin ecosystem, thereby eliminating ambiguity around the company's objectives.
- Bitcoin Treasury Accumulation: Since implementing its Bitcoin-focused strategy, Nakamoto has accumulated a Bitcoin treasury worth over $500 million and made strategic investments across multiple international markets, demonstrating its strong financial position in the Bitcoin sector.
- Subsidiary Operations: The healthcare business will continue operations through its wholly-owned subsidiary Kindly LLC, ensuring a clear division between healthcare and Bitcoin operations, which enhances overall operational efficiency.
- Future Development Plans: Nakamoto aims to build a global portfolio of Bitcoin-native companies through disciplined capital accumulation and acquisitions, intending to provide commercial and financial infrastructure for the next generation of capital markets.
See More
TG Therapeutics Reports $616 Million Revenue for FY 2025, Shares Surge 11.6%
- Strong Financial Performance: TG Therapeutics reported preliminary total global revenue of approximately $616 million for FY 2025, with Q4 U.S. net product revenue for BRIUMVI at about $182 million, indicating robust market performance that is expected to boost shareholder confidence.
- Significant Stock Surge: Following the earnings report, TG Therapeutics shares jumped 11.6% to $31.10 on Wednesday, reflecting investor optimism about the company's growth potential, which may attract more capital inflow.
- Positive Market Reaction: Despite a broader market decline with the Nasdaq Composite falling over 200 points, TG Therapeutics' strong financial data allowed it to stand out among numerous stocks, showcasing its competitiveness in the biopharmaceutical sector.
- Optimistic Future Outlook: Although the financial figures are unaudited, the preliminary results suggest that the company is poised for continued growth, particularly in the marketing of its BRIUMVI product, which could further enhance its market share.
See More
KindlyMD Authorizes Share Repurchase Program to Enhance Financial Flexibility
- Repurchase Program Initiation: KindlyMD's Board has authorized a share repurchase program aimed at enhancing financial stability through flexible capital allocation, reflecting confidence in the company's long-term value.
- Capital Allocation Optimization: The program allows for stock repurchases through various means such as open-market purchases and private transactions, with management adjusting strategies based on market conditions and capital needs to achieve optimal capital utilization.
- Shareholder Value Enhancement: Chairman and CEO David Bailey stated that the repurchase program not only demonstrates confidence in the company's future but also aims to create durable value for all shareholders through effective capital deployment.
- Strategic Integration: KindlyMD's merger with its Bitcoin subsidiary Nakamoto Holdings has formed a diversified entity focused on healthcare innovation and Bitcoin treasury management, further enhancing its competitive position in the market.
See More
KindlyMD Approves Stock Buyback Plan, Shares Rise in Pre-Market Trading
Share Repurchase Program: Kindly MD, Inc. (NAKA) has announced a board-approved share repurchase program for its outstanding common stock, allowing the company to buy back shares in various ways.
Board Flexibility: The board retains the option to modify or terminate the share repurchase program as deemed necessary.
Stock Performance: In pre-market trading, NAKA shares are priced at $0.38, reflecting a 4.21 percent increase on the Nasdaq.
Disclaimer: The views expressed in the announcement are those of the author and do not necessarily represent Nasdaq, Inc.
See More
KindlyMD Approves Stock Buyback Initiative
Share Repurchase Program: KindlyMD's board has authorized a share repurchase program allowing the company to buy back its outstanding common stock through various means, including open-market purchases and block trades.
Flexibility in Repurchases: The program does not commit KindlyMD to a specific number of shares and allows for modifications based on market conditions, share price, and other factors.
See More
KindlyMD Rebrands to Nakamoto, Aligns with Bitcoin Strategy
- Corporate Rebranding: KindlyMD has rebranded to Nakamoto to align its corporate identity with its long-term strategy in the Bitcoin ecosystem, continuing healthcare operations through wholly-owned subsidiary Kindly LLC to ensure business continuity.
- Bitcoin Treasury Accumulation: The company has established a Bitcoin treasury worth over $500 million, enhancing its scalable operating and treasury platform through strategic investments and treasury asset allocations across multiple international markets.
- Share Repurchase Program: KindlyMD has authorized a share repurchase program, indicating confidence in its intrinsic value and potentially enhancing earnings per share by reducing the number of shares outstanding.
- Financial Performance: KindlyMD reported a GAAP EPS of -$0.42, missing expectations by $0.41, with revenue of $0.39 million slightly below projections, reflecting challenges during its transformation process.
See More
Nakamoto Inc. Rebrands to Align with Bitcoin Strategy, Holds Over $500 Million in Bitcoin Treasury
- Corporate Rebranding: Nakamoto Inc. has changed its name from KindlyMD, Inc. to Nakamoto Inc. to better align with its long-term strategy in the Bitcoin ecosystem, thereby eliminating ambiguity around the company's objectives.
- Bitcoin Treasury Accumulation: Since implementing its Bitcoin-focused strategy, Nakamoto has accumulated a Bitcoin treasury worth over $500 million and made strategic investments across multiple international markets, demonstrating its strong financial position in the Bitcoin sector.
- Subsidiary Operations: The healthcare business will continue operations through its wholly-owned subsidiary Kindly LLC, ensuring a clear division between healthcare and Bitcoin operations, which enhances overall operational efficiency.
- Future Development Plans: Nakamoto aims to build a global portfolio of Bitcoin-native companies through disciplined capital accumulation and acquisitions, intending to provide commercial and financial infrastructure for the next generation of capital markets.
See More
TG Therapeutics Reports $616 Million Revenue for FY 2025, Shares Surge 11.6%
- Strong Financial Performance: TG Therapeutics reported preliminary total global revenue of approximately $616 million for FY 2025, with Q4 U.S. net product revenue for BRIUMVI at about $182 million, indicating robust market performance that is expected to boost shareholder confidence.
- Significant Stock Surge: Following the earnings report, TG Therapeutics shares jumped 11.6% to $31.10 on Wednesday, reflecting investor optimism about the company's growth potential, which may attract more capital inflow.
- Positive Market Reaction: Despite a broader market decline with the Nasdaq Composite falling over 200 points, TG Therapeutics' strong financial data allowed it to stand out among numerous stocks, showcasing its competitiveness in the biopharmaceutical sector.
- Optimistic Future Outlook: Although the financial figures are unaudited, the preliminary results suggest that the company is poised for continued growth, particularly in the marketing of its BRIUMVI product, which could further enhance its market share.
See More
KindlyMD Authorizes Share Repurchase Program to Enhance Financial Flexibility
- Repurchase Program Initiation: KindlyMD's Board has authorized a share repurchase program aimed at enhancing financial stability through flexible capital allocation, reflecting confidence in the company's long-term value.
- Capital Allocation Optimization: The program allows for stock repurchases through various means such as open-market purchases and private transactions, with management adjusting strategies based on market conditions and capital needs to achieve optimal capital utilization.
- Shareholder Value Enhancement: Chairman and CEO David Bailey stated that the repurchase program not only demonstrates confidence in the company's future but also aims to create durable value for all shareholders through effective capital deployment.
- Strategic Integration: KindlyMD's merger with its Bitcoin subsidiary Nakamoto Holdings has formed a diversified entity focused on healthcare innovation and Bitcoin treasury management, further enhancing its competitive position in the market.
See More
KindlyMD Approves Stock Buyback Plan, Shares Rise in Pre-Market Trading
Share Repurchase Program: Kindly MD, Inc. (NAKA) has announced a board-approved share repurchase program for its outstanding common stock, allowing the company to buy back shares in various ways.
Board Flexibility: The board retains the option to modify or terminate the share repurchase program as deemed necessary.
Stock Performance: In pre-market trading, NAKA shares are priced at $0.38, reflecting a 4.21 percent increase on the Nasdaq.
Disclaimer: The views expressed in the announcement are those of the author and do not necessarily represent Nasdaq, Inc.
See More
KindlyMD Approves Stock Buyback Initiative
Share Repurchase Program: KindlyMD's board has authorized a share repurchase program allowing the company to buy back its outstanding common stock through various means, including open-market purchases and block trades.
Flexibility in Repurchases: The program does not commit KindlyMD to a specific number of shares and allows for modifications based on market conditions, share price, and other factors.
See More
